Scarica l'app Stockscreener
374.15
3.55%
12.82
Dopo l'orario di chiusura:
372.67
-1.48
-0.40%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$361.33
Aprire:
$364.74
Volume 24 ore:
2.48M
Relative Volume:
0.91
Capitalizzazione di mercato:
$201.93B
Reddito:
$37.30B
Utile/perdita netta:
$7.80B
Rapporto P/E:
26.02
EPS:
14.3793
Flusso di cassa netto:
$8.60B
1 W Prestazione:
+6.05%
1M Prestazione:
+13.98%
6M Prestazione:
+14.20%
1 anno Prestazione:
+26.04%
Intervallo 1D:
$363.39
$375.15
Intervallo di 1 settimana:
$354.16
$375.15
Portata 52W:
$269.77
$391.29
Amgen Inc Stock (AMGN) Company Profile
Nome
Amgen Inc
Settore
Industria
Telefono
(805)447-1000
Indirizzo
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
374.15 | 195.44B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,213.91 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
263.04 | 611.36B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
261.07 | 444.60B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
129.56 | 317.37B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
159.90 | 299.04B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-21 | Iniziato | Canaccord Genuity | Hold |
| 2026-03-10 | Iniziato | Jefferies | Hold |
| 2026-02-20 | Iniziato | Barclays | Equal Weight |
| 2026-01-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-05 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-11-24 | Ripresa | Truist | Hold |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-03 | Ripresa | Raymond James | Mkt Perform |
| 2025-05-20 | Ripresa | Guggenheim | Neutral |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-14 | Downgrade | Truist | Buy → Hold |
| 2024-09-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Aggiornamento | Truist | Hold → Buy |
| 2023-10-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-17 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Ripresa | BofA Securities | Neutral |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-04-24 | Reiterato | Oppenheimer | Outperform |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Reiterato | Truist | Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Underperform |
| 2022-10-31 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-09 | Reiterato | Barclays | Equal Weight |
| 2022-02-09 | Reiterato | Jefferies | Buy |
| 2022-02-09 | Reiterato | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Reiterato | Oppenheimer | Outperform |
| 2022-02-09 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-09-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Iniziato | Daiwa Securities | Buy |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Aggiornamento | Truist | Hold → Buy |
| 2020-10-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Downgrade | Truist | Buy → Hold |
| 2020-10-08 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Ripresa | Guggenheim | Neutral |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-03-30 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-17 | Ripresa | Morgan Stanley | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-11-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-08-19 | Downgrade | Mizuho | Buy → Neutral |
| 2019-05-23 | Aggiornamento | Citigroup | Neutral → Buy |
Mostra tutto
Amgen Inc Borsa (AMGN) Ultime notizie
Amgen Inc. $AMGN Stake Lessened by Fulton Bank N.A. - MarketBeat
Amgen Secures Court Halt to Colorado Board’s Price Cap on Enbrel - Bloomberg Law News
Amgen Wins Order Blocking Colorado's Enbrel Price Cap - Law360
Judge blocks Colorado’s first-of-its-kind price cap on Amgen’s Enbrel By Reuters - Investing.com
Judge blocks Colorado's first-of-its-kind price cap on Amgen's Enbrel - Reuters
Controversial drug at center of multibillion-dollar Amgen deal faces more questions after paper retracted - The Business Journals
AMGNAMGEN Inc Options - Finviz
Amgen Inc. highlights its biotech pipeline as investors track long-term growth prospects - AD HOC NEWS
BMO Capital maintains Amgen stock rating citing Tavneos concerns - Investing.com
BMO Capital maintains Amgen stock rating citing Tavneos concerns By Investing.com - Investing.com Canada
Amgen or Biogen: Which Biotech Stock Appears Better Poised? - TradingView
BMO Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $400 - Moomoo
USS Investment Management Ltd Acquires 3,681 Shares of Amgen Inc. $AMGN - MarketBeat
Mizuho Highlights Amgen (AMGN) Pipeline Potential With MariTide and Olpasiran - Yahoo Finance
IFM Investors Pty Ltd Increases Holdings in Amgen Inc. $AMGN - MarketBeat
InflaRx seeks to fill void left by Amgen’s Tavneos in Europe - European Biotechnology Magazine
Amgen (AMGN) Faces EU Push To Revoke Tavneos Approval - Yahoo Finance
Viridian may have edge over Amgen in eye drug showdown, analysts argue - BioPharma Dive
Amgen Faces Fresh Pressure After NEJM Retracts Trial Behind $459 Million Drug - GuruFocus
Medication used to treat heart failure recalled nationwide - The Hill
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know - Yahoo Finance
Pathway Financial Advisers LLC Sells 5,382 Shares of Amgen Inc. $AMGN - MarketBeat
Alphabet Just Joined the Dow Jones Industrial Average. 3 Dow Dividend Stocks to Buy Now. - The Motley Fool
Forum Financial Management LP Sells 2,792 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Stock Weighs Strong Run Against Mixed Valuation Signals - Yahoo Finance
Heart and Kidney Medications Recalled Nationwide—Over 900,000 Bottles Affected - EatingWell
Medical journal retracts paper on Amgen’s Tavneos drug trial after FDA findings - Reuters
Amgen (AMGN) Faces Setback as Clinical Trial Article Retracted - GuruFocus
Amgen Drug Tavneos’ Main Study Retracted by Medical Journal - Bloomberg.com
Recall alert: Nearly 1M bottles of kidney, heart medications recalled - Boston 25 News
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease - Benzinga
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $427 - Moomoo
Amgen Bases as Healthcare Ramps for NASDAQ:AMGN by TradeStation - TradingView
Matrix Asset Advisors Inc. NY Sells 3,739 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen advances obesity pipeline focus, shares hold near recent highs - AD HOC NEWS
Amgen Inc. $AMGN Holdings Lifted by Fort Washington Investment Advisors Inc. OH - MarketBeat
Amgen sets late-stage obesity data milestone, shares on watch for Wegovy and Zepbound competition - AD HOC NEWS
BLINCYTO from Amgen Inc.immunotherapy that reshapes leukemia care - Ad-hoc-news.de
FDA Approves Viridian’s Thyroid Eye Disease Drug, Competitor to a Blockbuster Amgen Med - MedCity News
Amgen Recalls Corlanor and Sensipar Tablets Over Foreign Substance RiskNews and Statistics - IndexBox
Amgen Sunday strategy focus, stock and pipeline under long-term scrutiny - Ad-hoc-news.de
Janney Montgomery Scott LLC Decreases Stake in Amgen Inc. $AMGN - MarketBeat
Nicholas Wealth LLC. Takes $1.16 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Bought by Pictet Asset Management Holding SA - MarketBeat
Nearly 1 million bottles of heart and kidney medication recalled over foreign substance found on tablets - Fox Business
Price to book forward of Amgen Inc. – NASDAQ:AMGN - TradingView
The Evenity from Amgen Inc.osteoporosis therapy with a defined 12-month window - Ad-hoc-news.de
Amgen updates phase 2 obesity data, shares closely watched by health investors - Ad-hoc-news.de
Amgen (AMGN) Faces EU Withdrawal Risk for Tavneos Due to Data In - GuruFocus
900,000 Bottles of Heart and Kidney Medications Recalled For 'Unexpected Foreign Matter' in Bottles - People.com
Nearly 1 million bottles of medication used to treat heart failure recalled nationwide - PIX11
Amgen Inc Azioni (AMGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):